Results 231 to 240 of about 132,795 (279)

Paediatric Antiretroviral Drug Targets

Infectious Disorders - Drug Targets, 2011
HIV-1 infection is a major problem for children in lower income countries. The benefit of early antiretroviral (ARV) therapy started within 12 weeks of life is well documented. Although the development of new drug classes give alternative options for highly treatment experienced patients there is inadequate pharmacokinetic knowledge regarding the ...
Slogrove, Amy L., Rabie H., Cotton M.
openaire   +2 more sources

Antiretroviral drugs in pediatrics

The Indian Journal of Pediatrics, 2001
The advent of potent drugs to treat HIV and the development of increasingly effective treatment strategies have resulted in dramatic improvements in the prognosis and quality of life for HIV-infected children. The purpose of this article is to provide the primary care physicians with practical information on antiretroviral drugs that are currently used
C, Rongkavilit, B I, Asmar
openaire   +2 more sources

Drug interactions with antiretrovirals

Current HIV/AIDS Reports, 2004
The recent development of new antiretroviral drugs, along with the evolution in clinical practice guidelines that include the recommendation of the use of three- to four-drug combination regimens for achieving optimal suppression of viral replication, has focused clinicians on the relevance of drug-drug interactions in the chronic care of HIV-infected ...
Linda M, Catanzaro, Judianne C, Slish, Robert, DiCenzo, Gene D, Morse   +3 more
openaire   +2 more sources

Drug-Drug Interactions: Antiretroviral Drugs and Recreational Drugs

Recent Patents on CNS Drug Discovery, 2015
With the advances in antiretroviral (ARV) therapy, patients with Human Immunodeficiency Virus (HIV) infection are living longer, however, some patients encounter co- morbidities which sometimes require treatment. Therefore, during the treatment with ARV drugs these patients could take several recreational drugs (e.g.
Orietta, Staltari, Christian, Leporini, Benedetto, Caroleo, Emilio, Russo, Antonio, Siniscalchi, Giovambattista, De Sarro, Luca, Gallelli   +6 more
openaire   +2 more sources

Drug interactions with antiretrovirals

Current Infectious Disease Reports, 2000
The rapid development of new antiretroviral drugs, along with the evolution in clinical practice toward the recommended use of three- to four-drug combination regimens for achieving optimal suppression of viral replication, has brought the relevance of drug-drug interactions to the forefront of care for HIV-infected individuals.
openaire   +2 more sources

Antiretroviral Drug Resistance Mutations in Antiretroviral‐Naive Prisoners

Clinical Infectious Diseases, 2002
We assessed the incidence of antiretroviral drug resistance in a cohort of 25 antiretroviral-naive, human immunodeficiency virus-positive inmates in Massachusetts. Silent mutations, unexpected mutations at resistant sites, and resistance mutations were recorded. Among these inmates, we found a prevalence of drug resistance mutations that was equivalent
David R, Stone, Colleen, Corcoran, Alysse, Wurcel, Barbara, McGovern, James, Quirk, Arthur, Brewer, Lorraine, Sutton, Richard T, D'Aquila   +7 more
openaire   +2 more sources

Antiretroviral Drug Trials

Science, 1997
While Joep M. A. Lange’s Policy Forum ([25 Apr., p. 548][1]) raises many of the problems faced by clinical trialists in developing effective therapies for human immunodeficiency virus (HIV) infection, he offers no solutions.
Alasdair Breckenridge, Valerie Kitchen, Janet H. Darbyshire   +2 more
openaire   +1 more source

Antiretroviral drugs for AIDS

The Lancet, 1996
Treatment of HIV disease with antiretroviral agents has changed considerably. We now know that monotherapy is not the best strategy in most cases to combat rapid turnover of virus and development of resistance (the exception being mother-to-child transmission) and various combination drug regimens are being explored.
openaire   +2 more sources

Antiretroviral and Statin Drug-Drug Interactions

Cardiology in Review, 2009
Patients living with the human immunodeficiency virus (HIV) are at risk for dyslipidemia as a result of the disease itself and from certain classes of antiretroviral therapy. The protease inhibitors and non-nucleoside reverse transcription inhibitors have been associated with elevated triglycerides, total, and low-density lipoprotein cholesterol with ...
openaire   +2 more sources

Reformulation of existing antiretroviral drugs

Current Opinion in HIV and AIDS, 2013
In the last decade, there has been marked progress in the treatment of HIV/AIDS. Today, nearly 10 million people are receiving ART. Yet, there are several opportunities for the enhancement of current antiretroviral (ARV) drugs by developing new formulations, which could increase bioavailability, reduce pharmacokinetic variability, and reduce the total ...
Jaideep A, Gogtay, Geena, Malhotra
openaire   +2 more sources